Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits

被引：0

作者：

Buttgereit, Frank ^{[1
,2
,3
]}

Palmowski, Andriko ^{[1
,2
,3
,4
,5
]}

Esen, Idil ^{[6
]}

Brouwer, Elisabeth ^{[6
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Dept Rheumatol & Clin Immunol, Berlin, Germany

[4] Univ Copenhagen, Parker Inst, Sect Biostat & Evidence Based Res, Copenhagen, Denmark

[5] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA USA

[6] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷 / 04期

关键词：

D O I：

10.1002/art.42414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：489 / 492

页数：4

共 50 条

[41] GIANT CELL ARTERITIS WITH MULTIPLE COMORBIDITIES: SUCCESSFUL TREATMENT WITH TOCILIZUMAB
Athanassiou, P.
Athanassiou, L.
Katsavouni, C.
Banti, T.
Tzanavari, A.
Kostoglou-Athanassiou, I.
OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S407 - S408
[42] Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
Ohta, Ryuichi
Nishikura, Nozomi
Ikeda, Hirotaka
Sano, Chiaki
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
[43] Tocilizumab in patients with giant cell arteritis: for whom and for how long?
Quinn, Kaitlin A.
LANCET RHEUMATOLOGY, 2021, 3 (05): : E314 - E315
[44] Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy
Misako Higashida-Konishi
Mitsuhiro Akiyama
Tatsuya Shimada
Satoshi Hama
Tatsuhiro Oshige
Keisuke Izumi
Hisaji Oshima
Yutaka Okano
Rheumatology International, 2023, 43 : 545 - 549
[45] Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Pratyasha Saha
Denesh Srikantharajah
Arvind Kaul
Nidhi Sofat
Journal of Medical Case Reports, 16
[46] The long-term use of tocilizumab in giant cell arteritis
Coath, Fiona Louise
Mukhtyar, Chetan
RHEUMATOLOGY, 2021, 60 (10) : 4447 - 4449
[47] Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?
Samson, M.
Bonnotte, B.
REVUE DE MEDECINE INTERNE, 2018, 39 (02): : 75 - 77
[48] TOCILIZUMAB IN COMBINATION WITH 8 WEEKS OF PREDNISONE FOR GIANT CELL ARTERITIS
Unizony, S.
Matza, M.
Jarvie, A.
Fernandes, A.
Stone, J. H.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 123 - 123
[49] Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Calderon-Goercke, Monica
Loricera, Javier
Prieto-Pena, Diana
Castaneda, Santos
Aldasoro Caceres, Vicente
Villa, Ignacio
Humbria, Alicia
Moriano, Clara
Romero-Yuste, Susana
Narvaez, Javier
Gomez-Arango, Catalina
Perez Pampin, Eva
Melero, Rafael
Becerra-Fernandez, Elena
Revenga, Marcelino
Alvarez-Rivas, Noelia
Galisteo, Carles
Sivera, Francisca
Olive-Marques, Alejandro
Alvarez del Buergo, Maria
Marena-Rojas, Luisa
Fernandez-Lopez, Carlos
Navarro, Francisco
Raya, E.
Galindez-Agirregoikoa, Eva
Arca, Beatriz
Solans-Laque, Roser
Conesa, Arantxa
Hidalgo, Cristina
Vazquez, Carlos
Andres Roman-Ivorra, Jose
Lluch, Pau
Manrique, Sara
Vela, P.
de Miguel, Eugenio
Torres-Martin, Carmen
Carlos Nieto, Juan
Ordas-Calvo, Carmen
Salgado-Perez, Eva
Luna-Gomez, Cristina
Javier Toyos-Saenz De Miera, F.
Fernandez-Llanio, Nagore
Garcia, Antonio
Larena, Carmen
Varela-Garcia, Maria
Aurrecoechea, Elena
Ortiz-Sanjuan, Francisco
Luis Hernandez, Jose
Angel Gonzalez-Gay, Miguel
Blanco, Ricardo
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[50] Vision loss in patients with giant cell arteritis treated with tocilizumab
Jennifer Amsler
Iveta Kysela
Christoph Tappeiner
Luca Seitz
Lisa Christ
Godehard Scholz
Odile Stalder
Florian Kollert
Stephan Reichenbach
Peter M. Villiger
Arthritis Research & Therapy, 23

← 1 2 3 4 5 →